Gianfranco Parati1,2, Martino Francesco Pengo3, Carolina Lombardi3,4. 1. Sleep Disorder Centre, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, IRCCS Istituto Auxologico Italiano, Ospedale San Luca, Via Magnasco, 2, Milan, Italy. gianfranco.parati@unimib.it. 2. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. gianfranco.parati@unimib.it. 3. Sleep Disorder Centre, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, IRCCS Istituto Auxologico Italiano, Ospedale San Luca, Via Magnasco, 2, Milan, Italy. 4. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Abstract
PURPOSE OF REVIEW: Obstructive sleep apnea (OSA) and hypertension are two phenomena deeply linked together and, although a causal relationship has been suggested, a recent meta-analysis showed only a very modest effect of OSA treatment on blood pressure (BP). However, a vast number of randomized controlled trials published so far share some limitations, mainly of methodological nature: neither OSA nor BP is always assessed in a standardized way. Moreover, compliance with OSA treatment is often sub-optimal making the results of these trials difficult to interpret. RECENT FINDINGS: Recent studies have shown that antihypertensive drugs can reduce BP more than OSA treatment, showing a better compliance profile and very few side effects. Considering the importance of reducing the overall cardiovascular risk of OSA patients, a more careful management of patient's antihypertensive medication could allow a better BP control also in this condition. In addition, greater efforts should be made to improve patient's acceptance of OSA treatment with the aim of improving their compliance.
PURPOSE OF REVIEW: Obstructive sleep apnea (OSA) and hypertension are two phenomena deeply linked together and, although a causal relationship has been suggested, a recent meta-analysis showed only a very modest effect of OSA treatment on blood pressure (BP). However, a vast number of randomized controlled trials published so far share some limitations, mainly of methodological nature: neither OSA nor BP is always assessed in a standardized way. Moreover, compliance with OSA treatment is often sub-optimal making the results of these trials difficult to interpret. RECENT FINDINGS: Recent studies have shown that antihypertensive drugs can reduce BP more than OSA treatment, showing a better compliance profile and very few side effects. Considering the importance of reducing the overall cardiovascular risk of OSA patients, a more careful management of patient's antihypertensive medication could allow a better BP control also in this condition. In addition, greater efforts should be made to improve patient's acceptance of OSA treatment with the aim of improving their compliance.
Authors: Esther I Schwarz; Christian Schlatzer; Valentina A Rossi; John R Stradling; Malcolm Kohler Journal: Chest Date: 2016-07-21 Impact factor: 9.410
Authors: G Parati; M Di Rienzo; M R Bonsignore; G Insalaco; O Marrone; P Castiglioni; G Bonsignore; G Mancia Journal: J Hypertens Date: 1997-12 Impact factor: 4.844
Authors: Miguel-Angel Martínez-García; Francisco Capote; Francisco Campos-Rodríguez; Patricia Lloberes; María Josefa Díaz de Atauri; María Somoza; Juan F Masa; Mónica González; Lirios Sacristán; Ferrán Barbé; Joaquín Durán-Cantolla; Felipe Aizpuru; Eva Mañas; Bienvenido Barreiro; Mar Mosteiro; Juan J Cebrián; Mónica de la Peña; Francisco García-Río; Andrés Maimó; Jordi Zapater; Concepción Hernández; Nuria Grau SanMarti; Josep María Montserrat Journal: JAMA Date: 2013-12-11 Impact factor: 56.272
Authors: Benson Wu; Wassim Tarraf; Douglas M Wallace; Ariana M Stickel; Neil Schneiderman; Susan Redline; Sanjay R Patel; Linda C Gallo; Yasmin Mossavar-Rahmani; Martha L Daviglus; Phyllis C Zee; Gregory A Talavera; Daniela Sotres-Alvarez; Hector M González; Alberto Ramos Journal: PLoS One Date: 2022-04-04 Impact factor: 3.752
Authors: Richard Staats; Inês Barros; Dina Fernandes; Dina Grencho; Cátia Reis; Filipa Matos; João Valença; João Marôco; António Bugalho de Almeida; Cristina Bárbara Journal: Front Physiol Date: 2020-03-13 Impact factor: 4.566